Dental Practice EBITDA

Dental practices continue to be one of the most durable and sought-after verticals within U.S. healthcare services M&A. For owners evaluating strategic options, understanding how EBITDA is calculated, normalized, and underwritten is essential. EBITDA, not top-line revenue, remains the primary metric governing dental practice valuation, buyer competition, and ultimate transaction pricing.

This report outlines how EBITDA is assessed in general dentistry, the adjustments buyers consider acceptable, and the operational factors that shape the quality of earnings. These benchmarks offer a clear framework for owners preparing for a sale process in today’s environment.

What you will learn in this report:

Why EBITDA Matters Most in Dental Valuation

Dental practices generate revenue through a mix of hygiene services, preventive care, restorative work, elective procedures, and ancillary offerings. These revenue streams are predictable and recurring; however, valuation outcomes ultimately rely on EBITDA, as buyers use cash-flow durability and operational efficiency to underwrite future performance.

For general dentistry, EBITDA is the single most important metric for:

• Setting valuation expectations
• Determining where a practice falls within the 5–8× add-on or 9–11× platform range
• Comparing practices of different scales
• Assessing risk related to staffing, payer mix, and scheduling efficiency
• Evaluating integration costs and synergies post-close

Buyers emphasize EBITDA quality, not simply the raw number. Two practices with the same EBITDA can achieve very different multiples based on composition, stability, and defensibility.¹

How Buyers Calculate and Normalize Dental Practice EBITDA

EBITDA for general dentistry is evaluated through a consistent normalization process. Buyers focus on credibility, recurrence, and comparability across transactions.

Standardized 2025 EBITDA Multiples for General Dentistry

The dental sector has remained resilient through recent market volatility, with valuation floors stable and growing sponsor engagement heading into 2026. Many investment bankers project 2026 will be the most robust M&A year for dentistry since 2002.² Buyers continue to prioritize essential, consumer-facing care models such as dental, home-based care, and behavioral health, each demonstrating predictable utilization and margin visibility.

Dental and ophthalmology practices can see multiples reaching 9× to 12× EBITDA, among the highest across all healthcare specialties.³

General dentistry specifically trades within the following ranges:

Dental Practice Valuation Benchmarks (General Dentistry)

Importantly, headline multiples have stayed broadly constant over the last two years; the more meaningful shift has been dispersion. Premium practices continue to command premium valuations, while average practices encounter more friction, including longer timelines, greater diligence scrutiny, and increased negotiation on price and structure.¹

Factors That Shape Dental Practice EBITDA Quality

EBITDA quality, not just the quantum, determines valuation outcomes. Buyers closely evaluate several operational characteristics that influence EBITDA durability.

1. Hygiene Program Strength

Hygiene is the backbone of recurring dental EBITDA. Buyers examine:

• Recall adherence rates
• Hygiene-to-doctor production ratios
• Consistency of preventive volumes
• Scheduling optimization and chair utilization

A predictable hygiene program directly supports strong underwriting and multiple expansion.

2. Provider Mix and Clinical Throughput

High-quality EBITDA is supported by:

• Multiple productive hygienists
• Efficient doctor-provider collaboration
• Stable associate tenure
• Balanced case type distribution

Concentration risk, especially reliance on a single owner-doctor, can dilute perceived stability. In 2026, provider risk has moved from a “consideration” to a primary decision driver. It was also one of the top reasons DSOs stepped away from transactions in 2025.¹

3. Payer Mix and Reimbursement Stability

EBITDA quality improves when practices maintain:

• Balanced PPO and commercial mix
• Limited exposure to highly discounted plans
• Predictable government payer dynamics (when relevant)
• Growing cash-pay treatment categories

Commercial strength and diversified fee schedules signal less volatility. Buyers are underwriting payer mix more conservatively in 2026, particularly where state Medicaid policy direction could affect rates, eligibility, or benefits. Reimbursement exposure is now evaluated as a state-level variable.¹

4. Operational and Management Infrastructure

Infrastructure maturity is one of the strongest drivers of EBITDA quality:

• Documented SOPs
• KPI dashboards
• Centralized scheduling
• Standardized clinical workflows
• Revenue cycle management protocols
• Compliance programs

These operational systems reduce integration risk and often justify upper-range multiples.

5. Technology and Digital Adoption

Modern digital workflows support higher EBITDA margins and consistency:

• Digital radiography
• Intraoral scanning
• Cloud-based practice management systems
• Automated patient communication tools
• Analytics-driven scheduling and recall systems

Artificial intelligence is now routinely deployed for radiograph interpretation and treatment-plan optimization; automation has reduced the administrative burden tied to insurance verification and appointment reminders. Together, these innovations have expanded margins and created a valuation environment in which well-run offices can command higher EBITDA multiples than in prior years.²

New EBITDA Risk Factors in 2026

Several dynamics specific to the 2026 operating environment are reshaping how buyers assess EBITDA defensibility. Practice owners preparing for a process should understand and address these proactively.

Tariff-Driven Supply Cost Pressure

Tariffs introduced a layer of unpredictability for dental operators in 2025. Price pass-through on imported dental supplies and equipment components typically lags, meaning practices that went to market early in 2025 with strong trailing performance sometimes experienced mid-year margin compression during diligence as suppliers repriced.

Buyers now examine trailing twelve-month EBITDA carefully for evidence of this timing mismatch and evaluate whether cost increases are one-time or structural.¹

The “Silver Wave” and Doctor-to-Doctor Sale Risk

An aging cohort of dental practice owners is approaching retirement, simultaneously with a shift in early-career dentist behavior. ADA Health Policy Institute data shows that overall dental practice ownership declined from 84.7% (2005) to 72.5% (2023), with markedly lower ownership rates among dentists 44 and younger.¹

Meanwhile, rising dental school tuition costs increased approximately 30% at public institutions and 38% at private institutions between 2014-15 and 2023-24, increasing debt loads for new graduates.¹ As a result, owners who assumed a traditional associate buy-in would be their exit path are increasingly finding that path unreliable, making institutional buyers a more important consideration.

Recapitalization Cycles Creating Acquisition Urgency

In TUSK’s 2026 buy-side survey, 78% of DSO respondents indicated anticipated recapitalizations within 12 to 36 months, reinforcing emphasis on adding high-quality EBITDA ahead of exit events.¹ This creates real urgency on the buy side: DSOs approaching a recap window are motivated to partner with premium assets quickly to strengthen their story, which benefits well-positioned sellers.

Offer Structure Complexity

Cash versus equity mix is playing a larger role in transaction outcomes. In 2025-2026, it became increasingly common for offers to include joint-venture equity, hold co-equity rolled into the parent platform, or hybrid structures combining both. The spread between a best offer and a middle offer has also widened materially, reflecting differing views on provider risk, add-back credibility, and capital structures.¹

EBITDA Scalability and Practice Size

Buyers across the dental sector consistently value EBITDA scale. Larger practices with multi-location density achieve premium multiples due to lower integration risk and stronger administrative infrastructure.

Platform vs. Add-On EBITDA Dynamics

Valuation outcomes vary by transaction type, and EBITDA characteristics influence where a practice fits in buyer strategy. Platform transactions command premium valuation ranges due to scale and infrastructure maturity, while add-ons are priced based on integration fit and EBITDA stability. The distinctions below reflect how buyers evaluate each type.

Market Dynamics Affecting Dental EBITDA in 2025

Multiple sources, including VMG Health’s January 2026 DSO M&A report and TUSK Practice Sales’ Q1 2026 Dental M&A Market Report, outline consistent themes shaping dental EBITDA entering 2026:

• Deal volume expected to accelerate. 61% of surveyed DSOs reported their private equity backers expect a moderate or high increase in acquisition activity in 2026.¹
• Premium assets maintain strong multiples. Practices with clean earnings, stable provider coverage, and scalable operations are generating competitive processes with 6+ offers on average through structured sale processes.¹
• Recapitalization cycles are an active catalyst. 78% of buy-side respondents indicated anticipated recapitalizations within 12-36 months, creating urgency to add durable EBITDA ahead of exit windows.¹
• Macro conditions have improved. The Federal Reserve lowered the federal funds target range to 3.50%-3.75% in December 2025, improving financing conditions and lowering buyer hurdle rates for competitive processes.¹
• Specialty expansion is accelerating. Orthodontics, oral surgery, pediatric dentistry, and endodontics are attracting growing investment due to higher case complexity, favorable margin profiles, and cross-referral synergies.
• State-level regulation is intensifying compliance focus. Buyers are scrutinizing corporate practice of dentistry rules, fee-splitting prohibitions, and Medicaid benefit structures on a state-by-state basis, benefiting practices with strong documentation.²
• Dental remains among the most active healthcare verticals. Dental deals represented well over 100 transactions annually in each of the past several years, driven largely by add-on acquisitions by established platforms.⁵

Dental remains one of the most active verticals due to its recurring revenue, broad fragmentation, and scalability.

How Practices Can Improve EBITDA Before a Transaction

Dental practices aiming for top-quartile valuation outcomes benefit from a structured pre-process approach. These actions strengthen EBITDA quality, often as influential as EBITDA size.

Outlook for 2025–2026

The 2026 dental M&A environment is set up to be the most active in over two decades.² Buy-side acquisition mandates are rising, financing conditions have improved, and recapitalization timelines are creating urgency for DSOs to add high-quality EBITDA. At the same time, the structural trend of declining solo practice ownership among younger dentists and an aging cohort of boomer-generation owners is steadily increasing the supply of practices coming to market.

The standardized EBITDA multiples for general dentistry remain 9–11× for platforms and 5–8× for add-ons, and analysts broadly expect these ranges to hold through 2026 and into 2027.^2,5 However, the dispersion between best and worst offers has widened, making process quality and advisor selection more consequential than at any prior point in this cycle.

Practices with recurring hygiene revenue, multi-location scale, AI-enabled technology infrastructure, documented provider continuity plans, and defensible earnings normalization will be best positioned to command premium valuations and generate competitive processes over the next 12–18 months.